Respiratory Syncytial Virus-related Death in Children With Down Syndrome

Löwensteyn, Yvette N; Phijffer, Emily; Simons, Juliette V. L.; Scheltema, Nienke M.; Mazur, Natalie I; Nair, Harish; Bont, Louis

doi:10.1097/inf.0000000000002666

Cited by 29 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This includes increased mortality secondary to RSV and now to COVID-19 infections. [198][199][200][201][202][203][204]. Additionally, these diseases may manifest at earlier ages and greater severity in people with DS.…”

Section: Immune System Disordersmentioning

confidence: 99%

Opportunities, barriers, and recommendations in Down syndrome research

Hendrix¹,

Amon

Abbeduto

et al. 2021

TRD

View full text Add to dashboard Cite

BACKGROUND: Recent advances in medical care have increased life expectancy and improved the quality of life for people with Down syndrome (DS). These advances are the result of both pre-clinical and clinical research but much about DS is still poorly understood. In 2020, the NIH announced their plan to update their DS research plan and requested input from the scientific and advocacy community. OBJECTIVE: The National Down Syndrome Society (NDSS) and the LuMind IDSC Foundation worked together with scientific and medical experts to develop recommendations for the NIH research plan. METHODS: NDSS and LuMind IDSC assembled over 50 experts across multiple disciplines and organized them in eleven working groups focused on specific issues for people with DS. RESULTS: This review article summarizes the research gaps and recommendations that have the potential to improve the health and quality of life for people with DS within the next decade. CONCLUSIONS: This review highlights many of the scientific gaps that exist in DS research. Based on these gaps, a multidisciplinary group of DS experts has made recommendations to advance DS research. This paper may also aid policymakers and the DS community to build a comprehensive national DS research strategy.

show abstract

Section: Immune System Disordersmentioning

confidence: 99%

Opportunities, barriers, and recommendations in Down syndrome research

Hendrix¹,

Amon

Abbeduto

et al. 2021

TRD

View full text Add to dashboard Cite

show abstract

“…Moreover, these individuals are known to be at higher risk of respiratory tract infections, particularly respiratory syncytial virus and influenza infections. 2 , 3 Infections are a leading cause of death in DS along with congenital heart disease. 4 Therefore, timely, evidence-based analyses of SARS-CoV-2 infection in DS are warranted.…”

Section: Introductionmentioning

confidence: 99%

Individuals with Down syndrome hospitalized with COVID-19 have more severe disease

Malle

Gao

Hur

et al. 2021

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, these individuals are known to be at higher risk of respiratory tract infections, particularly respiratory syncytial virus and influenza infections. 1,2 Therefore, timely, evidence-based analyses of SARS-CoV-2 infection in DS are warranted.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Hospitalization is More Frequent and Severe in Down Syndrome and Affects Patients a Decade Younger.

Malle

Gao

Bouvier

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Individuals with rare disorders, like Down syndrome (DS) are historically understudied. Currently, it is not known how COVID-19 pandemic affects individuals with DS. Herein, we report an analysis of individuals with DS who were hospitalized with COVID-19 in the Mount Sinai Health System in New York City, USA. Methods. In this retrospective, single-center study of 4,615 patients hospitalized with COVID-19, we analyzed all patients with DS admitted in the Mount Sinai Health System. Hospitalization rates, clinical and outcomes were assessed. Findings. Contrary to an expected number of one, we identified six patients with DS. We found that patients with DS are at an 8.9-fold higher risk of hospitalization with COVID-19 when compared to non-DS patients. Hospitalized DS individuals are on average 10 years younger than non-DS patients with COVID-19. Moreover, type 2 diabetes mellitus appears to be an important driver of this susceptibility to COVID-19. Finally, patients with DS have more severe outcomes than controls, and are more likely to progress to sepsis in particular. Interpretation. We demonstrate that individuals with DS represent a higher risk population for COVID-19 compared to the general population and conclude that particular care should be taken for both the prevention and treatment of COVID-19 in these patients. Funding. National Institute of Allergy and Infectious Diseases

show abstract

Respiratory Syncytial Virus-related Death in Children With Down Syndrome

Abstract: • Severe hypoxemia requires SpO 2 <92% or advanced O 2 support (high-flow nasal cannula, helium/oxygen, CPAP, mechanical ventilation.

Cited by 29 publications

References 37 publications

Opportunities, barriers, and recommendations in Down syndrome research

Opportunities, barriers, and recommendations in Down syndrome research

Individuals with Down syndrome hospitalized with COVID-19 have more severe disease

COVID-19 Hospitalization is More Frequent and Severe in Down Syndrome and Affects Patients a Decade Younger.

Contact Info

Product

Resources

About